John  Wrangle  to  Immunoconjugates
                            
                            
                                This is a "connection" page, showing publications  John  Wrangle  has written about  Immunoconjugates.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.177
         
        
        
     
 
    
        
        - 
            A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1559-1569.
            
            
                Score: 0.177